| Serial Number | 97152371 |
| Word Mark | LONSUBIQ |
| Filing Date | Thursday, December 2, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, November 14, 2023 |
| Registration Number | 7215876 |
| Registration Date | Tuesday, November 14, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 29, 2023 |
| Goods and Services | Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE) |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 052, 051, 005, 018, 006, 044, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 6, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CSL Behring GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Party Name | CSL Behring GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Party Name | CSL Behring GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Event Date | Event Description |
| Tuesday, November 14, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, November 14, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, August 29, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 29, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 9, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, July 27, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, June 27, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, June 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, June 26, 2023 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Thursday, June 15, 2023 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Thursday, June 15, 2023 | INQUIRY TO SUSPENSION E-MAILED |
| Thursday, June 15, 2023 | SUSPENSION INQUIRY WRITTEN |
| Thursday, June 15, 2023 | SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION |
| Thursday, December 1, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, December 1, 2022 | LETTER OF SUSPENSION E-MAILED |
| Thursday, December 1, 2022 | SUSPENSION LETTER WRITTEN |
| Saturday, November 5, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, November 5, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, November 4, 2022 | ASSIGNED TO LIE |
| Thursday, September 22, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 8, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, September 8, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, September 8, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, September 8, 2022 | ASSIGNED TO EXAMINER |
| Monday, December 6, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, December 6, 2021 | NEW APPLICATION ENTERED |